Prognostic factors of liver metastases from uveal melanoma by Kodjikian, Laurent et al.
Graefe’s Arch Clin Exp Ophthalmol
(2005) 243: 985–993
DOI 10.1007/s00417-005-1188-8
CLINICAL INVESTIGATION
Laurent Kodjikian
Jean-Daniel Grange
Stéphano Baldo
Stéphanie Baillif
Justus G. Garweg
Michel Rivoire
Received: 8 December 2004
Revised: 24 March 2005
Accepted: 29 March 2005
Published online: 13 May 2005
# Springer-Verlag 2005
Prognostic factors of liver metastases
from uveal melanoma
Abstract Objectives: This study was
designed to assess survival and iden-
tify prognostic factors for liver me-
tastases diagnosed by systematic
screening in uveal melanoma patients.
Methods: Among 602 consecutive
patients treated over 10 years for
uveal melanoma and followed by
systematic semi-annual hepatic
screening (abdominal ultrasonogra-
phy), 63 (10.5%) developed liver
metastases; these patients form the
basis of this study. Factors including
patient demographics, characteristics
of the uveal tumor, metastasis-free
interval, severity of liver metastatic
involvement, and treatments of me-
tastases were studied retrospectively
regarding their prognostic value,
using univariate (Kaplan-Meier
method) and multivariate (Cox
model) analyses. Results: Thirty-
five patients (55.6% of the metastatic
population) received systemic che-
motherapy or best supportive care
only; 14 patients (22.2% of the
metastatic population) diagnosed with
diffuse liver involvement had cyto-
reductive surgery and intra-arterial
chemotherapy; 14 (22.2% of the
metastatic population) had complete
surgical removal of liver metastases
followed by postoperative intra-arte-
rial chemotherapy. No significant
surgical complications were experi-
enced. The median overall survival
after diagnosis of liver metastases was
15 months. It reached 25 months for
selected patients with complete re-
section (P=0.0002). In this cohort of
63 patients, ten or fewer preopera-
tively diagnosed metastases and pri-
mary uveal melanoma not involving
the ciliary body were independently
associated with better prognosis.
Conclusions: This study suggests
that selected patients with screened
liver metastases from uveal melanoma
may benefit from aggressive treat-
ment, including surgery. The two
independent favorable prognostic
factors are fewer than ten metastases
at screening and the absence of ciliary
body involvement.
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Introduction
Uveal melanoma is the most common primary intraocular
malignancy in adults. It arises from uveal melanocytes
residing in the uveal stroma, and accounts for 70% of all
primary ocular cancers [29]. The incidence of uveal mela-
noma in the French population has been estimated to be
0.73 per 100,000, its overall prevalence being 7.4 per
100,000 [30, 34]. Metastases from uveal melanoma occur
in a significant number of treated patients (6.5–35%) [7, 8,
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21]. For most patients, the liver is the primary and only site
involved at the time of detection of systemic metastases
[18]. Prognosis is reported to be very poor, depending above
all on liver involvement, since no systemic treatment has
been proven to be effective [2, 5, 6, 11]. Only a few prog-
nostic factors for survival have been identified. Age, short
time interval between diagnosis of primary uveal melanoma
and metastasis, and importance of liver metastatic burden
have shown a negative impact on survival, whereas patients
diagnosed at regular follow-up survived significantly longer
[3, 5, 6, 11, 13, 23, 25]. It is well established nowadays that
screening examination is advocated for all patients affected
by uveal melanoma [5, 6]. Therefore, criteria regarding the
severity of liver metastatic involvement [poor performance
status, elevated percentage of hepatic replacement, large
metastasis diameter, and abnormalities in liver function tests
(LFTs)] no longer seem to be applicable. Moreover, most
published series have been biased due to patient selection
criteria.
In the present study, we retrospectively reviewed the
files of a complete series of consecutive patients treated at a
single institution for uveal melanoma, in order to identify
prognostic factors and to evaluate survival in patients with
liver metastases detected by systematic screening. We in-
cluded both previously studied factors and new ones, es-
pecially uveal tumor characteristics.
Patients and methods
Patients
Between June 1, 1983 and December 31, 1996, 602 con-
secutive patients suffering from primary uveal melanoma
were registered in the Department of Ophthalmology at
Croix-RousseHospital, ClaudeBernardUniversity, in Lyon,
France. All patients were followed at regular 6-month
intervals with clinical examination and ocular and abdom-
inal ultrasonography. The compliance with the follow-up
was high, with an estimated rate of missed appointments of
only 5% [12]. If any abnormality was detected, a total body
computed tomography (CT) scan was performed, to obtain
an objective morphologic assessment. Of these 602 pa-
tients, 63 developed histologically or cytologically proven
metastases to the liver as primary extra-ocular metastatic
site, representing a rate of 10.5% during the 14 years of the
study period. The 3- and 5-year cumulative risk of metas-
tases were 5.8% (SE 2.4%) and 17.3% (SE 3.7%), re-
spectively. None of these 63 patients was lost to follow-up.
All these patients were consecutively treated at Léon Bérard
Cancer Centre in Lyon, France, until January 1, 2003.
All 63 patients with diagnosis of liver metastases from
uveal melanoma underwent a multidisciplinary treatment
program and were seen by the same surgeon to assess the
question of surgical removal of liver metastases. Patients
with diffuse metastases on the CT scan were not operated
on and received systemic chemotherapy or best supportive
care (meaning no specific therapy) only. Other patients un-
derwent laparotomy. Selection criteria for liver resection
were as follows: (1) medical fitness, (2) no signs of dis-
seminated disease, and (3) tumor anatomically confined to
the liver with 30–40% of normal parenchyma that could
be preserved after complete tumor resection. When com-
plete resection was not possible because of diffuse liver
involvement (miliary metastatic liver disease seen at open-
sky surgery and/or intraoperative ultrasonography), partial
debulking surgery was performed followed by implanta-
tion of an intra-arterial catheter for postoperative chemo-
therapy. Each time it was possible, patients underwent
complete liver metastasis resection, implantation of an
intra-arterial catheter and postoperative intra-arterial che-
motherapy using fotemustine (100 mg/m2 infused over
4 h every week or every 2 weeks in case of platelet de-
crease, over 2–4 months) or cisplatin (80 mg/m2 infused
over 4 h every week or every 2 weeks in case of platelet
decrease, over 2–4 months).
Methods
Medical records were reviewed for all patients to determine
the prognostic factors that significantly influenced survival
after first diagnosis of liver metastases. The following in-
formation was collected: gender, age at uveal melanoma
treatment and age at metastasis treatment, performance
status (Karnofsky index), anatomic location, TNM tumor
categories and pathologic data of the primary uveal mela-
noma when available, type of uveal melanoma treatment,
ocular recurrence, sites of systemic metastases, time inter-
val between initial tumor treatment and diagnosis of metas-
tases (called metastasis-free interval), symptoms from
metastases, metastasis diagnosis, LFTs (including serum
aspartate and alanine aminotransferase, alkaline phospha-
tase and lactate dehydrogenase levels), percentage of he-
patic replacement, number of liver metastases, largest liver
metastasis diameter, morbidity and mortality related to
metastasis treatment, and overall survival period after uveal
melanoma treatment and after metastasis diagnosis. The
performance status is classically categorized into three groups:
essentially asymptomatic patients (Karnofsky index 100-
90; equivalent to Eastern Cooperative Oncology group
(ECOG) 0 [17]], symptomatic patients [Karnofsky index
80-60; ECOG 1–2), and symptomatic patients with poor
performance status (Karnofsky index 50–10; ECOG 3–4).
The classification of uveal melanomas was obtained using
tumor thickness and largest tumor diameter (LTD). Patients
were allocated into three groups according to the “TNM
Classification of Malignant Tumors” (systematized no-
menclature of medicine ICD-O C69.3,4) [31]: patients with
T1 tumors (≤2.5 mm in thickness and ≤10 mm in LTD),
patients with T2 tumors (>2.5 and ≤10 mm in thickness and
>10 and ≤16 mm in LTD) and patients with T3 tumors (>10
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mm in thickness and/or >16 mm in LTD). This interna-
tional classification is almost equivalent to that used by the
COMS group, T1 corresponding to COMS “small” tumors,
T2 to “medium-sized” ones and T3 to “large” ones [32, 33].
Tumors including the ciliary body are termed hereafter
“ciliary body location” in this report.
Statistical assessment
Overall patient survival time was calculated from the date
of diagnosis of liver metastases to the time of death.
Observations relating to patients still alive on January 1,
2003 were censored after this date. Survival and time-to-
event rates, with standard error (SE), were calculated ac-
cording to the Kaplan-Meier method and compared using
the log rank test [9, 19]. On this basis, curves were con-
structed that depicted the probability of survival per month
following diagnosis of metastases. Moreover, we com-
pleted the univariate analysis by a univariate Cox regres-
sion model, indicating P-values, risk rates and 95%
confidence intervals in Table 3. A P-value below 0.05 was
considered to be statistically significant. Multivariate anal-
ysis, to evaluate the independence of prognostic factors,
utilized the Cox proportional hazards model, with sig-
nificance of the parameters estimated by the likelihood ratio
test [4]. Relative rates were calculated including 95% con-
fidence intervals. The variables tested in Cox regression
fulfilled the assumption of proportional hazards.
Results
Patient characteristics and follow-up evaluation
Of the 63 patients with liver metastases identified during
the study period, 30 were men and 33 women. The median
age was 57 years (range 28–81) at initial eye treatment and
61 years (range 31–85) at liver metastasis diagnosis. Fifty-
three patients died within the study period, with a median
time of 13 months (range 2.5–110) from diagnosis of liver
metastases to death. Thirty-eight patients (60%) survived
more than 1 year and 17 (27%) more than 2 years. Ten
patients were alive at the time of analysis; seven had
metastatic recurrence whereas three had no evidence of
disease. The median follow-up of these ten survivors was
29 months (range 16–110).
Primary uveal melanoma
The anatomic locations of primary uveal melanoma tumors
were 44 choroidal, 18 ciliary or ciliochoroidal, one irido-
ciliochoroidal tumors. Ocular tumor classification, includ-
ing thickness and LTD, is presented in Table 1. Initial and
further treatments for uveal melanoma are described in
Table 2. Fifteen patients (24%) with subsequent regrowth
of their uveal melanoma were retreated. Enucleation was
necessary in 21 patients. It was the first treatment in eight
patients; in other cases, it was consecutive to tumor re-
growth (eight patients), painful blindness with neovascular
glaucoma (five patients), complete retinal detachment as-
sociated with visual loss (one patient) or scleral necrosis
(one patient). Two patients had two causes. Pathologic data,
were available for 19 patients, showed the following dis-
tribution: three patients presented with epithelioid cells, five
with spindle cells, seven with mixed-cells and four with
total tumor necrosis.
Liver metastases
All but one patient were asymptomatic at the time of liver
metastasis diagnosis. Karnofsky index was known for all
patients, of whom 62 (98.4%) scored 100-90, and one
Table 1 Ocular tumor characteristics of 63 consecutive patients
treated for liver metastases from primary uveal melanoma
Ocular tumor characteristics Number Proportion (%)
Ciliary body involvement 19 30.2
Categories (according to TNM classification)a
T1 4 6.3
T2 35 55.6
T3 16 25.4
Thickness (mm)b
≤5 18 28.6
>5 38 60.3
≤10 45 71.4
>10 11 17.5
Largest basal tumor diameter (mm)c
≤10 19 30.2
>10 36 57.1
aMissing value for 8 cases
bMissing value for 7 cases
cMissing value for 8 cases
Table 2 Ocular treatments over time
Proton
beam
therapy
Brachytherapy Enucleation Other Total
1st treatment 38 12 8 5 63
2nd treatment 3 4 8 3 18
3rd treatment 1 5 1 7
Total 42 16 21 9
The “Brachytherapy” group included treatment with ruthenium
plaque or iridium
The “Other” group included transpupillary thermotherapy or
surgical removal of the tumor except enucleation
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(1.6%) scored 80. The metastatic work-up at the time of
diagnosis of extra-ocular metastases showed the following:
54 patients had metastases confined to the liver and nine
had metastases in the liver and at other sites, including lung
in five patients, bones in three, skin, pancreas and lymph
nodes in one. Seventeen patients (3% of the screened
population, 27% of the metastatic population) presented
ten or fewer liver metastases on the preoperative CT scan,
with a median number of three. All but one patient had less
than 25% of hepatic replacement by the tumor disease. This
patient was the only one in the series to have a more than 3
cm in diameter metastasis and abnormal LFTs.
The time interval between uveal melanoma treatment
and metastasis diagnosis ranged from 0 (4 patients) to 145
months (median time 29 months). Thirty-nine patients
(62%) developed liver metastases within 3 years. It took
longer than 5 years for 12 patients (19%), and even longer
than 10 years for two patients.
Metastasis treatment procedures
Twenty-eight patients (4.7% of the screened population
and 44.4% of the metastatic population) underwent liver
surgery. At direct examination and intraoperative ultraso-
nography, 14 patients were found to have diffuse miliary
metastatic liver disease that was missed by preoperative
imaging. They underwent partial metastatic debulking then
received postoperative intra-arterial chemotherapy with
fotemustine or cisplatin (mean 8 cycles, range 4–14 cycles).
Fourteen patients (2.3% of the screened population and
22.2% of the metastatic population) had complete remov-
al of liver metastases and 11 of these received postop-
erative intra-arterial chemotherapy with fotemustine or
cisplatin (mean 7 cycles, range 2–12 cycles). No significant
surgical complication was experienced. The remaining 35
patients with major liver involvement or diffuse metastases
(nine patients) after initial work-up were not operated on.
They received best supportive care (9 patients) or system-
ic chemotherapy (26 patients). Chemotherapy consisted of
an association of cisplatin, vinblastine and dacarbazine
(CVD), and in eight patients, dacarbazine alone in 14 pa-
tients and interferon±interleukin 2 in four patients.
Survival after liver metastases diagnosis
The median survival for the 63 patients was 47 months
(range 3–190 months) after primary uveal tumor treatment,
and 15 months (range 3–110 months) after liver metastasis
diagnosis. The overall survival rate after metastasis diag-
nosis was 59% (SE 6%) at 1 year, 29% (SE 6%) at 2 years
and 13% (SE 5%) at 4 years (Fig. 1). Median overall
survival after metastasis diagnosis reached 25 months
(range 11–110 months) for the 14 patients who underwent
complete resection, 16 months (range 3–35 months) for the
14 patients who underwent debulking surgery and 11months
(range 3–52 months) for the 35 patients who received
systemic chemotherapy or best supportive care (Fig. 2).
Predictors of survival in univariate analysis
(Table 3, univariate Cox regression model)
Patient demographics
Survival was not influenced by age (P=0.06) or by gender
(P=0.69) in the univariate analysis. Patients below the age
Fig. 1 Overall survival after diagnosis of liver metastases for all
patients and according to the preoperative number of liver metas-
tases (P=0.0002)-Kaplan-Meier estimator (n=63)
Fig. 2 Overall survival after diagnosis of liver metastases according
to metastasis treatment (P=0.0002)-Kaplan-Meier estimator (n=63)
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of 70 years had a 2-year overall survival of 34% (SE 7%)
compared with 7% (SE 6%) for patients older than 70
years. Performance status was not statistically significant,
since all but one patient belonged to the same group
(Karnofsky index 100–90) (Table 3).
Characteristics of the uveal tumor
The categories of primary uveal melanoma (T1/T2 versus
T3, P=0.78), including thickness (≤5 mm versus >5 mm,
P=0.85; ≤10 mm versus >10 mm, P=0.89) and LTD (≤10
mm versus >10 mm, P=0.91), as well as initial ocular
treatment (P=0.21) and ocular recurrence (P=0.85) were
Table 3 Univariate predictors
of outcome (univariate Cox
regression model)
aCI=confidence interval
Variable Number of patients Risk Rate 95% CIa P
Overall 63
Sex
Male 30 1.00
Female 33 0.89 0.52–1.55 0.69
Age at metastases diagnosis
≤70 48 1.00
>70 15 1.84 0.99–3.39 0.06
Primary tumor location
Non ciliary body 19 1.00
Ciliary body 44 1.70 0.92–3.11 0.09
Primary tumor TNM
T1 or T2 15 1.00
T3 38 1.10 0.57–2.14 0.78
Primary tumor thickness
≤5 mm 18 1.00
>5 mm 38 0.94 0.50–1.78 0.85
Primary tumor diameter
≤10 mm 19 1.00
>10 mm 36 1.04 0.55–1.95 0.91
Primary tumor treatment (1)
No enucleation 49 1.00
Enucleation 8 1.07 0.93−1.22 0.41
Primary tumor treatment (2)
Proton beam therapy 32 1.00
Brachytherapy 12
Thermotherapy or surgery 5 1.09 0.96–1.25 0.21
Enucleation 8
Ocular recurrence
Recurrence 15 1.00
No recurrence 48 0.94 0.48–1.83 0.85
Disease-free interval
≤24 months 26 1.00
>24 months 37 0.96 0.55–1.66 0.87
≤60 months 51 1.00
>60 months 12 1.62 0.83–3.19 0.18
Liver metastases treatment
Surgery 14 1.00
Intra-arterial chemotherapy 14 1.22 1.10–1.37 0.00002
Systemic chemotherapy or BSC 35
Number of liver metastases
≤10 17 1.00
>10 46 4.02 1.85–8.73 0.00006
989
not predictive of outcome in our series. Conversely, the
anatomic location of the primary uveal melanoma seemed
to influence outcome, in that melanomas involving the
ciliary body had a 2-year overall survival of 11% (SE 7%)
compared to 39% (SE 8%) for strictly choroidal melano-
mas (P=0.09) (Fig. 3).
Presentation and treatment of liver metastases
Neither a metastasis-free interval of less than 24 or 60
months after primary tumor treatment was predictive of
outcome (P=0.87 and P=0.18, respectively). Overall sur-
vival was also not associated with LFTs in this series, since
all but one patient presented normal levels. For the same
reasons, the percentage of hepatic replacement or the
largest metastasis diameter were not predictive of outcome
in this series. In contrast, the number of liver metastases
detected preoperatively (up to ten metastases) was a strong
indicator of outcome (P=0.00006) (Fig. 1). All 5-year
survivors in this study had maximally ten liver metastases
preoperatively uncovered. Ten (59%) of the 17 patients
with ten or fewer liver metastases belonged to the complete
liver metastases resection group, versus only four (9%) of
the 46 patients with more than ten liver metastases.
Lastly, complete resection of liver metastases noticeably
influenced outcome (P=0.00002) (Fig. 2). There was no
survival difference between the group treated by partial
metastasis resection and the group treated by systemic che-
motherapy or best supportive care (P=0.32).
Multivariate analysis of outcome (Table 4)
In a multivariate regression model including the number of
preoperative metastases, ciliary body location and age, the
number of metastases and ciliary body location were in-
dependently associated with survival (P<0.0001 and P=
0.017, respectively). Age was treated as a continuous vari-
able in the multivariate analysis only. In this model, the
Fig. 3 Overall survival (after metastases treatment) according to uveal melanoma location (P=0.084)-Kaplan-Meier estimator (n=63)
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treatment of metastases weighted similarly to the number
of preoperative metastases because of the high correlation
between the two variables. Indeed, the number of metas-
tases directly influenced the choice of liver metastasis
treatment (Table 4).
Discussion
The prognosis of metastatic uveal melanoma is poor.
Metastases to the liver are the life-limiting component of the
disease in the majority of patients [10, 11, 23, 27]. Thus,
median survival is 19 months for metastatic patients from
uveal melanoma with no liver involvement, but falls to 7
months after liver dissemination [11]. A few prognostic
factors have been identified to date, but they still remain
poorly understood. Only four studies have provided a
multivariate analysis of these factors [3, 5, 6, 13]. To sum
up, age above 50/55 years, male gender, short interval of
time between uveal melanoma diagnosis and metastasis
diagnosis, and severity of liver metastatic burden (poor
performance status, elevated percentage of hepatic replace-
ment, large metastasis diameter, and abnormalities in LFTs)
have been shown to have a negative impact on survival [3,
5, 6, 13, 23]. The limitation of most of these studies is that
they refer to limited numbers of metastatic patients, which
does not fit with complex regressionmodels such as the Cox
proportional hazards model [2, 11, 23]. Additionally, these
studies may suffer from selection biases, i.e. age [13, 25],
metastasis-free interval or metastasis location [1]; therefore,
results may not directly be compared or generalized. Beside
our series, only two studies with no obvious bias regarding
patient selection have been reported [5, 6]. In these studies,
however, metastasis treatment was mainly supportive care
or systemic chemotherapy, which is well known to be in-
sufficient in uveal melanoma metastases [3, 6, 13]. Surgery
was carried out in only 1–9% of the cases, compared with
44% in our series. The two reports showed that patients
diagnosed during screening examination survived signifi-
cantly longer [5, 6]. There is no evidence that screening
examination improves the outcome; nevertheless, it seems
nowadays advocated for all patients affected by uveal
melanoma [5, 6]. Since 1983, all our patients have been
followed semi-annually by clinical examination and liver
ultrasonography. As a consequence, all but one patient
diagnosed with liver metastasis was asymptomatic, had
good performance status, low hepatic replacement, and
normal LFTs. This justified conducting the present study to
determine new prognostic factors, applicable to metastatic
uveal melanoma patients selected by regular screening.
The strength of our study is that the series is population-
based and consecutive. All 602 patients affected by uveal
melanoma evaluated during the 14-year study period orig-
inated from a single centre (Croix-Rousse Hospital) and all
metastatic patients (63) were referred to a single institution
(Léon Bérard Cancer Center) in order to minimize phy-
sician-associated biases. This resulted in a quite significant
number of operated-on patients. We have tried to define
preoperative selection criteria, thanks to systematic CT
scan. The two main limitations of our study are the retro-
spective collection of data and the wide variety of therapy
protocols used thus precluding any definitive conclusion
on the treatment efficacy and indication. However, data
were collected from medical charts and systematic CT scan
reviewing, which leaves little scope for error. In addition,
we limited the number of variables studied in the Cox
model according to sample size. Despite these limitations,
we believe that our results may be extrapolated to the
treatment of other patients with liver metastatic uveal
melanoma. The metastatic population was not different in
term of primary tumor characteristics from our whole pop-
ulation [12, 24].
In our series, 10.5% of the screened patients (63 of 602)
were found to have liver metastases. Twenty-eight of them
(4.7% of the screened population and 44.4% of the metas-
tatic population) were selected for liver surgery and post-
operative intra-arterial chemotherapy. Fourteen patients
presented intraoperative miliary metastatic liver disease,
that was too small to be picked up by conventional imag-
ing. Finally, only 14 of these patients (2.3% of the screened
population and 22.2% of the metastatic population) were
able to undergo complete resection of liver metastases
Table 4 Overall survival of 63 incident cases of uveal melanoma with liver metastases
Factor Category Number Risk rate 95% CIa Pb
Number of metastases ≤10 17 1.00
>10 46 4.98 2.1–11.6 <0.0001
Melanoma location Not involving ciliary body 44 1.00
Involving ciliary body 19 2.20 1.2–4.1 0.017
Age (decades) Linearc NAd 1.01 0.99–1.04 0.285
Risk rates of death associated with number of metastases, ciliary body location and age (multivariate Cox model)
aCI=confidence interval
bLikelihood ratio test for heterogeneity
cAge was treated as a continuous variable. The relative rates in the table were taken from the linear model. Quadratic terms were also tested
and were not significant
dNA=not applicable
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without any major surgical complication. This selection
was based on the preoperative number of liver metastasis,
which seems to be a good indicator of severity of metastatic
burden. These patients consequently survived for a median
time of 25 months (P=0.0002), whereas the median re-
ported survival following detectable liver metastasis dis-
semination is only 2–9 months [5, 27]. Although these
results are somewhat disappointing according to the small
number of patients with benefit, this screening program is
considered nowadays as the most efficient and cost
effective. Furthermore, these results suggest that there is
a subgroup of metastatic patients who can benefit from
aggressive surgery. Lastly, more intensive work-up with
systematic use of staging laparoscopy may be of value to
improve liver assessment and patient selection, and to avoid
unnecessary laparotomy.
We individualized new prognostic factors in a multivar-
iate analysis. When building the regression model, we tried
to take into account different aspects relevant to the clinical
situation. To our knowledge, the influence of uveal mela-
noma characteristics (TNM tumor categories, tumor thick-
ness, LTD, location of primary uveal tumor and uveal
melanoma recurrence) on the survival of metastatic patients
has not been previously reported. LTD, which is known to
be the most important clinical risk factor for the develop-
ment of metastases among patients treated for primary
uveal melanoma [7, 15, 26, 28], is no longer of prognostic
relevance once metastases have occurred. In contrast,
ciliary body involvement, also known to worsen the
prognosis in patients affected by uveal melanoma [16, 22,
26], irrespective of tumor size, remained an independent
predictor of death after metastases occurrence in our series.
Tumors involving the ciliary body are recognized to be
more likely to harbor monosomy of chromosome 3 and
trisomy of chromosome 8q, a situation that is associated
with a very high risk of death [14, 20]. Clearly, tumor
genetics may represent an as yet unexplored confounder of
prognosis. Furthermore, we found that the preoperative
number of liver metastases was a significant independent
predictor of survival in our series. Patients with more than
10 metastases had a 4.8 times increased risk of death. This
threshold was arbitrarily chosen, in a will of simplification,
since this has no real signification on a disease biology
stand-point. Most of the patients had a smaller number of
metastases. The median number of preoperative metastases
in the subgroup of patients with fewer than ten metastases
was only three, and patients with more than ten were usu-
ally found to have a huge number. Among other factors,
this discrimination level should be used to select candidate
patients for surgery and multimodal treatment. Indeed, if
ten or fewer liver metastases are identified preoperatively,
laparotomy can therefore be attempted.
We postulate that our results would not have been
achieved without a systematic semi-annual hepatic screen-
ing that we therefore strongly advocate, since 1983, for all
patients suffering from uveal melanoma. More frequent
follow-up might be considered in high-risk patients, i.e.
those with ciliary body involvement. Nevertheless, semi-
annual screening ultrasound clearly was ineffective for
early detection of hepatic metastasis in most patients with
uveal melanoma. It is far more likely that tumor biology
and patient selection govern final outcome, rather than
screening ultrasound. Moreover, our present study was not
designed to assess the effectiveness of any treatment meth-
od, since therapy was not randomized. Nevertheless, there
is clearly a need for a rigorous selection of patients can-
didates for surgical treatment [25] since our data show that
complete surgical removal of metastases associated with
postoperative intra-arterial chemotherapy seems to be effec-
tive for prolonging survival in a limited selected group of
patients (2.3% of the screened population and 22.2% of
the metastatic population). Since no efficient medical treat-
ment is yet available for metastatic patients, these data
could serve as a basis for a randomized clinical trial
comparing non-surgical standard treatment and surgery in
patients with ten or fewer liver metastases. Better screen-
ing tests and more effective multimodality treatments are
required to improve survival in a larger number of uveal
melanoma patients with liver metastases.
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